Current Report Filing (8-k)
May 11 2020 - 4:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 11, 2020
NEPHROS,
INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware
|
|
001-32288
|
|
13-3971809
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
380
Lackawanna Place, South Orange, New Jersey 07079
(Address
of principal executive offices, including ZIP code)
(201)
343-5202
(Registrant’s
telephone number, including area code)
n/a
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, $0.001 par value
|
|
NEPH
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01.
|
Regulation
FD Disclosure.
|
On
May 11, 2020, Nephros, Inc. (the “Company”) announced that, due to the public health impact of the coronavirus outbreak
(COVID-19), its Annual Meeting of Stockholders (the “Annual Meeting”), to be held on Thursday, May 21, 2020 at 9:00
a.m., EDT, has been changed to a virtual meeting. Stockholders will not be able to attend the Annual Meeting in person this year.
A
copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by
reference herein.
Item
9.01.
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Nephros,
Inc.
|
|
|
|
Dated:
May 11, 2020
|
By:
|
/s/
Andrew Astor
|
|
|
Andrew
Astor
|
|
|
Chief
Financial Officer
|
Nephros (NASDAQ:NEPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nephros (NASDAQ:NEPH)
Historical Stock Chart
From Apr 2023 to Apr 2024